Eileen Brown

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. doi request reprint Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression
    Eileen Brown
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Int J Neuropsychopharmacol 12:773-82. 2009
  2. ncbi request reprint A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression
    Eileen B Brown
    Lilly Research Laboratories, Indianapolis, IN, USA
    J Clin Psychiatry 67:1025-33. 2006
  3. ncbi request reprint Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study
    Mauricio Tohen
    Lilly Research Laboratories, IN 46285, USA
    Am J Psychiatry 160:1263-71. 2003
  4. ncbi request reprint Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania
    Robert W Baker
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Br J Psychiatry 185:472-8. 2004
  5. ncbi request reprint Clinical relevance of depressive symptom improvement in bipolar I depressed patients
    Doug Williamson
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46221, USA
    J Affect Disord 92:261-6. 2006
  6. ncbi request reprint Acute dysphoric mania: treatment response to olanzapine versus placebo
    Robert W Baker
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    J Clin Psychopharmacol 23:132-7. 2003
  7. ncbi request reprint Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial
    Cherri Miner
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Clin Ther 24:417-33. 2002
  8. ncbi request reprint Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial
    Roy H Perlis
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 67:1747-53. 2006
  9. ncbi request reprint Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study
    Ferenc Martenyi
    Lilly Research Laboratories, Vienna, Austria
    J Clin Psychopharmacol 27:166-70. 2007
  10. ncbi request reprint Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study
    John H Heiligenstein
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Child Adolesc Psychopharmacol 16:207-17. 2006

Detail Information

Publications18

  1. doi request reprint Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression
    Eileen Brown
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Int J Neuropsychopharmacol 12:773-82. 2009
    ..There was no treatment difference in incidence of relapse. OFC-treated patients had more treatment-emergent adverse events and greater incidence of weight gain and hypercholesterolaemia...
  2. ncbi request reprint A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression
    Eileen B Brown
    Lilly Research Laboratories, Indianapolis, IN, USA
    J Clin Psychiatry 67:1025-33. 2006
    ..Determine the efficacy and tolerability of olanzapine/fluoxetine combination (OFC) for treatment of acute bipolar I depression compared with lamotrigine...
  3. ncbi request reprint Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study
    Mauricio Tohen
    Lilly Research Laboratories, IN 46285, USA
    Am J Psychiatry 160:1263-71. 2003
    ..Few double-blind trials have compared longer-term efficacy and safety of medications for bipolar disorder. The authors report a 47-week comparison of olanzapine and divalproex...
  4. ncbi request reprint Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania
    Robert W Baker
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Br J Psychiatry 185:472-8. 2004
    ..Few controlled studies examine the treatment of depressive features in mania...
  5. ncbi request reprint Clinical relevance of depressive symptom improvement in bipolar I depressed patients
    Doug Williamson
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46221, USA
    J Affect Disord 92:261-6. 2006
    ..Gaps remain between rating scale changes obtained in a clinical trial and what those results mean in clinical practice...
  6. ncbi request reprint Acute dysphoric mania: treatment response to olanzapine versus placebo
    Robert W Baker
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    J Clin Psychopharmacol 23:132-7. 2003
    ..Additional experience with putative mood stabilizers and atypical agents in mixed mania should include an exploration of their efficacy in treating both manic and depressive mood symptoms...
  7. ncbi request reprint Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial
    Cherri Miner
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Clin Ther 24:417-33. 2002
    ..Because the symptoms of premenstrual dysphoric disorder (PMDD) are limited to the luteal phase of the menstrual cycle, the potential benefit of luteal-phase dosing has been hypothesized...
  8. ncbi request reprint Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial
    Roy H Perlis
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 67:1747-53. 2006
    ..To compare olanzapine and risperidone in the treatment of nonpsychotic acute manic or mixed episodes...
  9. ncbi request reprint Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study
    Ferenc Martenyi
    Lilly Research Laboratories, Vienna, Austria
    J Clin Psychopharmacol 27:166-70. 2007
    ..9), and -36.6 (25.7) in the 20-mg fluoxetine, 40-mg fluoxetine, and placebo arms, respectively. Placebo response rate was substantially higher in this study than in a previously published fluoxetine trial of posttraumatic stress disorder...
  10. ncbi request reprint Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study
    John H Heiligenstein
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Child Adolesc Psychopharmacol 16:207-17. 2006
    ....
  11. ncbi request reprint Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder
    Stephen K Brannan
    Cyberonics, Houston, TX 77058, USA
    J Psychiatr Res 39:43-53. 2005
    ..The efficacy of duloxetine, a balanced and potent dual reuptake inhibitor of 5-HT and NE, was evaluated within a cohort of depressed patients with associated painful physical symptoms...
  12. ncbi request reprint Changes in energy after switching from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine
    Melissa J Joliat
    J Clin Psychopharmacol 24:464-7. 2004
  13. ncbi request reprint Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment
    Teri Pearlstein
    Women s Behavioral Health Program, Women and Infants Hospital, Providence, RI 02905 2499, USA
    Am J Obstet Gynecol 188:887-95. 2003
    ..The aim of this study was to use the data from two clinical trials to evaluate premenstrual dysphoric disorder symptom severity after the discontinuation of fluoxetine treatment...
  14. ncbi request reprint Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder
    Ferenc Martenyi
    Novartis Pharmaceuticals, Basel, Switzerland
    Br J Psychiatry 181:315-20. 2002
    ..Little is known about the effect of pharmacotherapy in the prevention of post-traumatic stress disorder (PTSD) relapse...
  15. ncbi request reprint Safety and efficacy of fluoxetine in patients who receive oral contraceptive therapy
    Stephanie C Koke
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Am J Obstet Gynecol 187:551-5. 2002
    ....
  16. ncbi request reprint Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression
    Cherri M Miner
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind 46285, USA
    J Clin Psychiatry 63:232-40. 2002
    ....
  17. ncbi request reprint Fluoxetine versus placebo in posttraumatic stress disorder
    Ferenc Martenyi
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind 46285, USA
    J Clin Psychiatry 63:199-206. 2002
    ..The patient population included both civilians and combat veterans...
  18. ncbi request reprint Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents
    Mary Nilsson
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Child Adolesc Psychopharmacol 14:412-7. 2004
    ..The aim of this study was to assess the safety of subchronic fluoxetine treatment for major depressive disorder (MDD) in children and adolescents...